Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 19/20 | 0.85 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.85 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.85 |
| ▸ | MELK | Q14680 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932325 | 0.95 | BCL6 (0.86) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL30713709 | 0.94 | BCL6 (0.85) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284171 | 0.93 | BCL6 (0.83) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL29508710 | 0.92 | BCL6 (1.00) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284237 | 0.92 | BCL6 (1.00) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL25228543 | 0.92 | BCL6 (0.82) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL30486070 | 0.92 | BCL6 (0.82) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284548 | 0.92 | BCL6 (0.75) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL21787648 | 0.92 | BCL6 (0.75) | BCL6CHRM4BCL6BMELKNCOR2 | |
| SCHEMBL20284544 | 0.92 | BCL6 (0.75) | BCL6CHRM4BCL6BMELKNCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734988-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF USE THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250127909-A1 | Compositions, Systems, and Methods for Modulating a Target Gene | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | disclosed |
| EP-4518903-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR MODULATING A TARGET GENE | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250066326-A1 | BCL6 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119486762-A | Compositions, systems, and methods for modulating a target gene | 小利兰·斯坦福大学托管委员会 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025007026-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4448487-A1 | BCL6 DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-117120096-A | Regulation of gene expression via transcription factor-chemical induction proximity (TF-CIP) | 小利兰·斯坦福大学托管委员会 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023215311-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR MODULATING A TARGET GENE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230304024-A1 | Modulation of Gene Expression Via Transcription Factor-Chemically Induced Proximity (TF-CIP) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-20230304024-A1 | Modulation of Gene Expression Via Transcription Factor-Chemically Induced Proximity (TF-CIP) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| EP-4240390-A1 | MODULATION OF GENE EXPRESSION VIA TRANSCRIPTION FACTOR-CHEMICALLY INDUCED PROXIMITY (TF-CIP) | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023114460-A1 | BCL6 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022098989-A1 | MODULATION OF GENE EXPRESSION VIA TRANSCRIPTION FACTOR-CHEMICALLY INDUCED PROXIMITY (TF-CIP) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098989-A1 | MODULATION OF GENE EXPRESSION VIA TRANSCRIPTION FACTOR-CHEMICALLY INDUCED PROXIMITY (TF-CIP) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-20210030740-A1 | B CELL LYMPHOMA 6 PROTEIN (BCL6) AS A TARGET FOR TREATING DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE | NORTHWESTERN UNIVERSITY (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066326-A1 | BCL6 DEGRADERS AND USES THEREOF | BCL6, BCL6B, BCL3 | BCL6 1/4885CHRM4 4855/4885BCL6B 2/4885 |
| US-20230304024-A1 | Modulation of Gene Expression Via Transcription Factor-Chemically Induced Proximity (TF-CIP) | CTCF, TFDP2, TEAD4 | BCL6 1015/4885CHRM4 4395/4885BCL6B 1429/4885 |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | BCL6 1/4885CHRM4 4574/4885BCL6B 2/4885 |
| US-20210030740-A1 | B CELL LYMPHOMA 6 PROTEIN (BCL6) AS A TARGET FOR TREATING DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE | BCL6, BCL6B, BCL3 | BCL6 1/4885CHRM4 4799/4885BCL6B 2/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | BCL6 1/4885CHRM4 4563/4885BCL6B 2/4885 |
| US-20250127909-A1 | Compositions, Systems, and Methods for Modulating a Target Gene | MYCBP, SNRPE, RPRD2 | BCL6 591/4885CHRM4 4126/4885BCL6B 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.